then click the Enroll button at the bottom of the page.
Target Audience
This activity is intended for Family Practitioners, Physician Assistants, Registered Nurses, Nurse Practitioners, and other Allied Health Professionals interested in the treatment of asthma.
Term of Approval
December 1, 2009 through November 30, 2010
Learning Objectives
1. Discuss the definition of asthma control as defined by the NAEPP asthma guidelines.
2. Identify cases of severe asthma and indicate management steps as directed by the NAEPP asthma guidelines.
3. Indicate best methods to monitor asthma control and adjust treatment.
Accreditation and Designation Statement
National Jewish HealthTM is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
National Jewish HealthTM designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Jewish HealthTM is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 12724. The entire activity is approved for a total of 1.8 Nursing Contact Hours.
Participating Faculty
Harold Nelson, MD
Chair CME Committee
Professor
Department of Medicine
National Jewish Health
Michael B. Foggs, MD,
Chief of Allergy, Asthma & Immunology
Advocate Health Centers
Advocate Health Care
President & CEO
Asthma & Allergy Insights, LLC
Chicago, IL
Joseph Spahn, MD
Assistant Professor
Department of Pediatrics
National Jewish Health
E. Rand Sutherland, MD, MPH
Head, Division of Pulmonary and Critical Care
National Jewish Health
Associate Professor of Medicine
National Jewish Health and University of Colorado Denver
Disclosure Information Listed for CME Content Development, Approval Committee and Participating Program Faculty
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all program faculty, content developers, CME approval committee, and medical writers in a position to control the content of this activity are expected to disclose any or not significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., Stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
All CME Educational Activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.
KEY
| A - Advisory Board | C - Consultant | I - Investigator | SP - Speaker |
David Beuther, MD
SP - AstraZeneca
Ronina Covar, MD
A - Merck, Inc
I - Ross Abbott
Michael Foggs, MD
A - ALCON, AstraZeneca, GlaxoSmithKline, SEPRACOR
SP - AstraZeneca, GlaxoSmithKline, Merck, Schering-Plough, SEPRACOR
Harold S. Nelson, MD
C - Abbott, AstraZeneca, Boehringer-Ingelheim, Dey, L.P., Dynavax Technologies, Dyson, Genentech, GlaxoSmithKline, Johnson & Johnson, MediciNova, Novartis, Schering- Plough, Sepracor, Teva
I - Altana, AstraZeneca, Boehringer-Ingelheim, Ception, Genentech, Novartis, Schering-Plough, Sepracor, Wyeth
Joseph Spahn, MD
C - AstraZeneca, GlaxoSmithKline
I - AstraZeneca
SP - GlaxoSmithKline, Merck
Rand Sutherland, MD, MPH
A - Dey, L.P., GlaxoSmithKline
C - GlaxoSmithKline, Schering-Plough
I - Boehringer-Ingelheim, Novartis
Commercial Support
This program was supported by an educational grant from GlaxoSmith Kline